Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
In our #WorldOsteoporosisDay patient survey over half of respondents believed that #fragilityfractures in older age are a result of an unlucky fall or accident. However, they can be the result of #osteoporosis. Find out more: https://t.co/jwiw2fDtSJ https
— UCB News (@ucb_news) 20.10.2018 -
Our new survey, launched today to mark #WorldOsteoporosisDay, has revealed that nearly two thirds of respondents had little or no knowledge of the condition. Discover more about #fragilityfractures and #osteoporosis at: https://t.co/mCp191WkP9 https://t.c
— UCB News (@ucb_news) 20.10.2018 -
If Osaka Castle started crumbling, all of Japan would be talking about it. However, in our #Osteoporosis patient survey, 60% of Japanese women over 60 said their healthcare professional had never spoken to them about #osteoporosis or #fragilityfractures.
— UCB News (@ucb_news) 19.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
